세계의 바이러스 벡터 및 플라스미드 DNA - 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Viral Vector and Plasmid DNA was estimated to be worth US$ 667 million in 2024 and is forecast to a readjusted size of US$ 4187 million by 2031 with a CAGR of 30.2% during the forecast period 2025-2031.

Viral Vector and Plasmid DNA Manufacturing refers to the upstream manufacturing processes essential for gene therapy, cell therapy, mRNA vaccines, and next-generation biologics. It includes the production of high-purity, high-expression plasmid DNA and the preparation of high-titer, functionally stable viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). These processes must be conducted under stringent GMP conditions, often using microbial or mammalian expression systems, and involve key steps such as fermentation, purification, quality control, and encapsulation. With the rapid advancement of biotechnology, this sector is evolving from lab-scale production to industrial-scale manufacturing, becoming a strategic focus for CDMOs and biotech firms worldwide.In this report, we only study the Viral Vector and Plasmid DNA used for research.

As the commercialization of cell and gene therapies accelerates, global demand for viral vectors and plasmid DNA continues to grow. An increasing number of CAR-T therapies, AAV-based gene therapies, and mRNA vaccine programs are advancing into clinical and commercial stages, positioning high-quality vector materials as critical bottleneck resources. Meanwhile, supportive government policies promoting the localization of gene therapy and vaccine production are driving investment in GMP-compliant vector platforms. The expanding CDMO market, stronger outsourcing trends among biotech companies, and process optimization efforts lowering production costs are jointly propelling this sector toward rapid development.

Despite strong demand, the sector faces technical and regulatory hurdles. Standardization remains limited, with cross-platform consistency in production still difficult to achieve. The bar for quality control is high, requiring strict management of viral safety, residual nucleic acids, and encapsulation efficiency. Moreover, premium GMP capacity is still dominated by a few multinational firms, while emerging players often face challenges in infrastructure investment, technical expertise, and talent acquisition. Regulatory scrutiny is also intensifying, lengthening development timelines and raising entry thresholds.

Clinical pipeline expansion and commercial product launches are the primary growth drivers for this field. In indications such as rare diseases, cancer immunotherapy, and neurological disorders, the use of AAV and lentiviral vectors is increasing significantly. At the same time, plasmid DNA is widely used as a starting template or precursor for mRNA, vaccines, nucleic acid drugs, and CRISPR-based therapies. Strategic partnerships between pharma and CDMO players are proliferating to develop modular, scalable manufacturing platforms that can support a diverse array of downstream applications.

This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vector and Plasmid DNA by region & country, by Type, and by Application.

The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

Segment by Type

• AAV
• Lentiviruses
• Retroviruses
• Adenoviruses
• DNA Plasmids
• Other

Segment by Application

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vector and Plasmid DNA in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Viral Vector and Plasmid DNA Product Introduction
• 1.2 Global Viral Vector and Plasmid DNA Market Size Forecast (2020-2031)
• 1.3 Viral Vector and Plasmid DNA Market Trends & Drivers
  • 1.3.1 Viral Vector and Plasmid DNA Industry Trends
  • 1.3.2 Viral Vector and Plasmid DNA Market Drivers & Opportunity
  • 1.3.3 Viral Vector and Plasmid DNA Market Challenges
  • 1.3.4 Viral Vector and Plasmid DNA Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Viral Vector and Plasmid DNA Players Revenue Ranking (2024)
• 2.2 Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025)
• 2.3 Key Companies Viral Vector and Plasmid DNA Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Viral Vector and Plasmid DNA Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Viral Vector and Plasmid DNA
• 2.6 Viral Vector and Plasmid DNA Market Competitive Analysis
  • 2.6.1 Viral Vector and Plasmid DNA Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Viral Vector and Plasmid DNA Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 AAV
  • 3.1.2 Lentiviruses
  • 3.1.3 Retroviruses
  • 3.1.4 Adenoviruses
  • 3.1.5 DNA Plasmids
  • 3.1.6 Other
• 3.2 Global Viral Vector and Plasmid DNA Sales Value by Type
  • 3.2.1 Global Viral Vector and Plasmid DNA Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Type (2020-2031)
  • 3.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Pharmaceutical and Biopharmaceutical Companies
  • 4.1.2 Academics and Research Institutes
• 4.2 Global Viral Vector and Plasmid DNA Sales Value by Application
  • 4.2.1 Global Viral Vector and Plasmid DNA Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Application (2020-2031)
  • 4.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Viral Vector and Plasmid DNA Sales Value by Region
  • 5.1.1 Global Viral Vector and Plasmid DNA Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Viral Vector and Plasmid DNA Sales Value by Region (2020-2025)
  • 5.1.3 Global Viral Vector and Plasmid DNA Sales Value by Region (2026-2031)
  • 5.1.4 Global Viral Vector and Plasmid DNA Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.2.2 North America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.3.2 Europe Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Viral Vector and Plasmid DNA Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.5.2 South America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.3.2 United States Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.4.2 Europe Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.5.2 China Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.6.2 Japan Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.7.2 South Korea Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.9.2 India Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Thermo Fisher Scientific
  • 7.1.1 Thermo Fisher Scientific Profile
  • 7.1.2 Thermo Fisher Scientific Main Business
  • 7.1.3 Thermo Fisher Scientific Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.1.4 Thermo Fisher Scientific Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Thermo Fisher Scientific Recent Developments
• 7.2 Lonza
  • 7.2.1 Lonza Profile
  • 7.2.2 Lonza Main Business
  • 7.2.3 Lonza Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.2.4 Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Lonza Recent Developments
• 7.3 Azenta Life Sciences
  • 7.3.1 Azenta Life Sciences Profile
  • 7.3.2 Azenta Life Sciences Main Business
  • 7.3.3 Azenta Life Sciences Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.3.4 Azenta Life Sciences Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Azenta Life Sciences Recent Developments
• 7.4 Revvity
  • 7.4.1 Revvity Profile
  • 7.4.2 Revvity Main Business
  • 7.4.3 Revvity Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.4.4 Revvity Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Revvity Recent Developments
• 7.5 VectorBuilder
  • 7.5.1 VectorBuilder Profile
  • 7.5.2 VectorBuilder Main Business
  • 7.5.3 VectorBuilder Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.5.4 VectorBuilder Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.5.5 VectorBuilder Recent Developments
• 7.6 Takara Bio
  • 7.6.1 Takara Bio Profile
  • 7.6.2 Takara Bio Main Business
  • 7.6.3 Takara Bio Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.6.4 Takara Bio Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Takara Bio Recent Developments
• 7.7 GenScript Biotech
  • 7.7.1 GenScript Biotech Profile
  • 7.7.2 GenScript Biotech Main Business
  • 7.7.3 GenScript Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.7.4 GenScript Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.7.5 GenScript Biotech Recent Developments
• 7.8 Gene Chem
  • 7.8.1 Gene Chem Profile
  • 7.8.2 Gene Chem Main Business
  • 7.8.3 Gene Chem Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.8.4 Gene Chem Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Gene Chem Recent Developments
• 7.9 Geno Meditech
  • 7.9.1 Geno Meditech Profile
  • 7.9.2 Geno Meditech Main Business
  • 7.9.3 Geno Meditech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.9.4 Geno Meditech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Geno Meditech Recent Developments
• 7.10 PackGene Biotech
  • 7.10.1 PackGene Biotech Profile
  • 7.10.2 PackGene Biotech Main Business
  • 7.10.3 PackGene Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.10.4 PackGene Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.10.5 PackGene Biotech Recent Developments
• 7.11 VIROVEK
  • 7.11.1 VIROVEK Profile
  • 7.11.2 VIROVEK Main Business
  • 7.11.3 VIROVEK Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.11.4 VIROVEK Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.11.5 VIROVEK Recent Developments
• 7.12 OriGen
  • 7.12.1 OriGen Profile
  • 7.12.2 OriGen Main Business
  • 7.12.3 OriGen Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.12.4 OriGen Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.12.5 OriGen Recent Developments
• 7.13 Vector BioLabs
  • 7.13.1 Vector BioLabs Profile
  • 7.13.2 Vector BioLabs Main Business
  • 7.13.3 Vector BioLabs Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.13.4 Vector BioLabs Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Vector BioLabs Recent Developments

8 Industry Chain Analysis

• 8.1 Viral Vector and Plasmid DNA Industrial Chain
• 8.2 Viral Vector and Plasmid DNA Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Viral Vector and Plasmid DNA Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Viral Vector and Plasmid DNA Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer